Shanghai Serum Bio-Technology Co., Ltd.

SHSE:688163 Stock Report

Market Cap: CN¥2.1b

Shanghai Serum Bio-Technology Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Tiejiong Fan

Chief executive officer

CN¥1.0m

Total compensation

CEO salary percentagen/a
CEO tenure9.3yrs
CEO ownership0.2%
Management average tenure2yrs
Board average tenure9.3yrs

Recent management updates

Recent updates

Earnings Not Telling The Story For Shanghai Serum Bio-Technology Co., Ltd. (SHSE:688163) After Shares Rise 44%

Oct 23
Earnings Not Telling The Story For Shanghai Serum Bio-Technology Co., Ltd. (SHSE:688163) After Shares Rise 44%

Optimistic Investors Push Shanghai Serum Bio-Technology Co., Ltd. (SHSE:688163) Shares Up 30% But Growth Is Lacking

Sep 03
Optimistic Investors Push Shanghai Serum Bio-Technology Co., Ltd. (SHSE:688163) Shares Up 30% But Growth Is Lacking

CEO

Tiejiong Fan (39 yo)

9.3yrs

Tenure

CN¥1,010,800

Compensation


Leadership Team

NamePositionTenureCompensationOwnership
Tiejiong Fan
GM & Directorno dataCN¥1.01m0.23%
CN¥ 4.6m
Shaoyang Li
Chief Financial Officer2yrsCN¥514.20k0.010%
CN¥ 210.3k
Qiong Cheng
Deputy GM & Board Secretary9.3yrsCN¥755.10k0.092%
CN¥ 1.9m
Hao Zhang
General Manager Assistantno dataCN¥428.50k0.065%
CN¥ 1.3m
Liangjun Peng
Deputy General Manager1.4yrsCN¥392.50k0.032%
CN¥ 666.0k

2.0yrs

Average Tenure

53yo

Average Age

Experienced Management: 688163's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Tiejiong Fan
GM & Director9.3yrsCN¥1.01m0.23%
CN¥ 4.6m
Yanping Jin
Supervisorno datano data0.065%
CN¥ 1.3m
Zhihe Fan
Chairman of the Board9.3yrsCN¥1.11m34.05%
CN¥ 701.2m
Yiming He
Director9.3yrsCN¥751.20k0.13%
CN¥ 2.7m
Lianzhong Zhu
Staff Supervisorno datano data0.046%
CN¥ 951.5k
Jie Zhou
Director5.8yrsno datano data

9.3yrs

Average Tenure

65yo

Average Age

Experienced Board: 688163's board of directors are considered experienced (9.3 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:58
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Serum Bio-Technology Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution